Hoarseness

Wegovy® (semaglutide) injection 2.4 mg is the first-and-only medicine indicated for both reduction of the risk of major adverse cardiovascular events (MACE) such as death, heart attack, or stroke and for long-term weight management1 The approval is based on the results of SELECT, the largest cardiovascular outcomes trial ever completed for people with obesity and known heart disease2 PLAINSBORO, N.J., March 8, 2024 /PRNewswire/ -- Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved an additional indication for Wegovy® to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight along with a reduced calorie diet and increased physical activity.1 This new indication adds to the prescribing label for Wegovy®, a prescription-only medicine previously approved help adults and children aged 12 years and older with obesity, or some adults with overweight who also have weight-related medical problems, to help them lose excess body weight and keep the weight off when used along with a reduced calorie diet and increased physical activity.1 Experience the full interactive Multichannel News Release here: "Today, we're taking a pivotal step forward in addressing some of the most pressing health issues of our time with the added indication for Wegovy®," said Doug Langa, Executive Vice President, Head of North America Operations, and President of Novo Nordisk Inc. "We recognize how important this moment is for the millions of people who live with excess weight or obesity and known heart disease, and we will continue to advance options that put their needs first. Reducing this risk is a key part of our commitment to driving change for this community, as we work to increase manufacturing capacity to responsibly supply this important medicine." The FDA decision is based on the results of the landmark SELECT phase 3 cardiovascular outcomes trial that examined the effect of adding Wegovy® 2.4 mg or placebo to cardiovascular standard of care in adults with overweight and obesity with established CVD and without diabetes.2 Wegovy® 2.4 mg significantly reduced the risk for first occurrence of a three-part composite MACE endpoint consisting of cardiovascular death, non-fatal heart attack, or non-fatal stroke.1,2 The primary composite outcome occurred in 6.5% of patients treated with Wegovy® and 8.0% with placebo. The estimated relative risk reduction of MACE was 20% vs placebo (HR 0.80 [95% CI: 0.72, 0.90] p <0.001, absolute risk reduction of 1.5% at 40 months, the mean follow-up duration).1,2 The reduction of MACE with Wegovy® was not impacted by age, sex, race, ethnicity, baseline BMI, or level of renal function impairment.1,2 Safety data collection was limited to serious adverse events (including death), adverse events leading to discontinuation, and adverse events of special interest.1,2 In the SELECT trial, the proportion of patients for whom serious adverse events were reported was 33.4% in patients randomized to Wegovy® 2.4 mg and 36.4% of patients receiving placebo.2 Sixteen percent (16%) of Wegovy®-treated patients and 8% of placebo-treated patients, respectively, discontinued study drug due to an adverse event.1 The most common adverse event leading to discontinuation was gastrointestinal disorders, occurring in 10% of patients in the Wegovy® group and 2% in the placebo group.2 "This approval is a significant decision because people living with excess weight or obesity and established cardiovascular disease and without diabetes have never had an FDA-approved treatment option that lowers weight and reduces the likelihood of another cardiovascular event," said Dr. A. Michael Lincoff, Professor of Medicine at Cleveland Clinic and the lead study author of the SELECT outcomes trial. "For healthcare professionals, this approval provides a new treatment option to help us address cardiovascular residual risk that remains for patients on current standard of care." Between 1999 and 2020, obesity-related cardiovascular disease deaths tripled in the U.S., according to the American Heart Association.3 In fact, more than one in three U.S. adults live with obesity,4 one of the leading risk factors contributing to heart disease and stroke.5 About the SELECT Trial SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) was a multicenter, randomized, double-blind, placebo-controlled, event-driven superiority trial designed to evaluate the efficacy of Wegovy® 2.4 mg versus placebo as an adjunct to cardiovascular standard of care for reducing the risk of major adverse cardiovascular events in people with established CVD with overweight or obesity with no prior history of diabetes.2 The trial, initiated in 2018, enrolled 17,604 adults and was conducted in 41 countries at more than 800 investigator sites.2 About Wegovy® (semaglutide) injection 2.4 mg What is Wegovy®? WEGOVY ® (semaglutide) injection 2.4 mg is an injectable prescription medicine used with a reduced calorie diet and increased physical activity: to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight. that may help adults and children aged 12 years and older with obesity, or some adults with overweight who also have weight-related medical problems, to help them lose excess body weight and keep the weight off. Wegovy ® contains semaglutide and should not be used with other semaglutide-containing products or other GLP-1 receptor agonist medicines. It is not known if Wegovy ® is safe and effective for use in children under 12 years of age. Important Safety Information What is the most important information I should know about Wegovy ® ? Wegovy ® may cause serious side effects, including: Possible thyroid tumors, including cancer. Tell your healthcare provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer. In studies with rodents, Wegovy ® and medicines that work like Wegovy ® caused thyroid tumors, including thyroid cancer. It is not known if Wegovy ® will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people Do not use Wegovy ® if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) Do not use Wegovy ® if: you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) you have had a serious allergic reaction to semaglutide or any of the ingredients in Wegovy ® Before using Wegovy ® , tell your healthcare provider if you have any other medical conditions, including if you: have or have had problems with your pancreas or kidneys have type 2 diabetes and a history of diabetic retinopathy have or have had depression, suicidal thoughts, or mental health issues are pregnant or plan to become pregnant. Wegovy ® may harm your unborn baby. You should stop using Wegovy ® 2 months before you plan to become pregnant are breastfeeding or plan to breastfeed. It is not known if Wegovy ® passes into your breast milk Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Wegovy ® may affect the way some medicines work and some medicines may affect the way Wegovy ® works. Tell your healthcare provider if you are taking other medicines to treat diabetes, including sulfonylureas or insulin. Wegovy ® slows stomach emptying and can affect medicines that need to pass through the stomach quickly. What are the possible side effects of Wegovy ® ? Wegovy ® may cause serious side effects, including: inflammation of your pancreas (pancreatitis). Stop using Wegovy ® and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without vomiting. You may feel the pain from your abdomen to your back gallbladder problems. Wegovy ® may cause gallbladder problems, including gallstones. Some gallstones may need surgery. Call your healthcare provider if you have symptoms, such as pain in your upper stomach (abdomen), fever, yellowing of the skin or eyes (jaundice), or clay-colored stools increased risk of low blood sugar (hypoglycemia), especially those who also take medicines for diabetes such as insulin or sulfonylureas. This can be a serious side effect. Talk to your healthcare provider about how to recognize and treat low blood sugar and check your blood sugar before you start and while you take Wegovy ®. Signs and symptoms of low blood sugar may include dizziness or light-headedness, blurred vision, anxiety, irritability or mood changes, sweating, slurred speech, hunger, confusion or drowsiness, shakiness, weakness, headache, fast heartbeat, or feeling jittery kidney problems (kidney failure). In people who have kidney problems, diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems to get worse. It is important for you to drink fluids to help reduce your chance of dehydration serious allergic reactions. Stop using Wegovy ® and get medical help right away, if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue, or throat; problems breathing or swallowing; severe rash or itching; fainting or feeling dizzy; or very rapid heartbeat change in vision in people with type 2 diabetes. Tell your healthcare provider if you have changes in vision during treatment with Wegovy ® increased heart rate. Wegovy ® can increase your heart rate while you are at rest. Tell your healthcare provider if you feel your heart racing or pounding in your chest and it lasts for several minutes depression or thoughts of suicide. You should pay attention to any mental changes, especially sudden changes in your mood, behaviors, thoughts, or feelings. Call your healthcare provider right away if you have any mental changes that are new, worse, or worry you The most common side effects of Wegovy ® may include: nausea, diarrhea, vomiting, constipation, stomach (abdomen) pain, headache, tiredness (fatigue), upset stomach, dizziness, feeling bloated, belching, low blood sugar in people with type 2 diabetes, gas, stomach flu, heartburn, and runny nose or sore throat. Please see Medication Guide and Prescribing Information, Including Boxed Warning, for Wegovy at About obesity and cardiovascular disease (CVD) Obesity is a serious chronic, progressive, and misunderstood disease that requires long-term management.6,7,8 One key misunderstanding is that this is a disease of lack of willpower, when in fact there is underlying biology that may impede people with obesity from losing weight and keeping it off.6,8 Obesity is influenced by a variety of factors, including genetics, social determinants of health, and the environment.9 The prevalence of overweight and obesity is a public health issue that has severe cost implications to healthcare systems.10,11 In the U.S., about 42% of adults live with obesity.4 CVD is the leading cause of death in the U.S.12 More than 800,000 people die from CVD each year in the U.S. (1 in every 3 deaths) with about 160,000 of these deaths occurring in people younger than 65 years.13 Obesity increases the risk of developing high blood pressure or high blood cholesterol, both contributing factors to CVD.14,15 Residual risk for another cardiovascular event in people with obesity and known heart disease remains despite treatment of known cardiovascular risk factors such as high blood pressure and high cholesterol according to standard of care treatments.16,17 Novo Nordisk's commitment to the obesity and cardiovascular community is a long-term one, and we are investing significantly to build capacity to meet increasing demand. Please visit WegovySupply.com for the latest information. About Novo Nordisk Novo Nordisk is a leading global healthcare company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity, rare blood, and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way. With U.S. headquarters in New Jersey and commercial, production and research facilities in seven states plus Washington DC, Novo Nordisk employs approximately 8,000 people throughout the country. For more information, visit novonordisk-us.com, Facebook, Instagram, and X. Novo Nordisk is committed to the responsible use of our semaglutide-containing medicines which represent distinct products with different indications, dosages, prescribing information, titration schedules, and delivery forms. These products are not interchangeable and should not be used outside of their approved indications. Further information References: Wegovy® (semaglutide) injection 2.4 mg Prescribing Information. Plainsboro, NJ: Novo Nordisk Inc.; 2024. Lincoff MA, Brown-Frandson K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389:2221-2232. Raisi‐Estabragh Z, Kobo O, Mieres JH, et al. Racial Disparities in Obesity‐Related Cardiovascular Mortality in the United States: Temporal Trends From 1999 to 2020. J Am Heart Assoc. 2023;12:e028409. Centers for Disease Control and Prevention. Adult obesity facts. Last accessed February 2024. Available at: . Centers for Disease Control and Prevention. Heart disease and stroke. Last Accessed: February 2024. Available at: . Kaplan LM, Golden A, Jinnett K, et al. Perceptions of barriers to effective obesity care: Results from the national action study. Obesity. 2018;26(1):61-69. Bray GA, Kim KK, Wilding JPH; World Obesity Federation. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev. 2017;18(7):715-723. Garvey WT, Mechanick JI, Brett EM, et al. American association of clinical endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22 Suppl 3:1-203. Centers for Disease Control and Prevention. Causes of Obesity. Last accessed: February 2024. Available at: . World Obesity Federation. World Obesity Atlas 2023. Last accessed: February 2024.Available at: . Centers for Disease Control and Prevention. Why it Matters. Last accessed: February 2024. Available at: . Centers for Disease Control and Prevention. Leading Causes of Death. Last accessed: February 2024. Available at: . MillionHearts. Costs & Consequences. Last accessed: February 2024. Available at: . Centers for Disease Control and Prevention. Health Effects of Overweight and Obesity. Last accessed: February 2024. Available at: . Centers for Disease Control and Prevention. Know Your Risk for Heart Disease. Last accessed: February 2024. Available at: . Powell-Wiley, Tiffany M., et al. "Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association." Circulation, vol. 143, no. 21, 25 May 2021. Dhindsa DS, et al. "The Evolving Understanding and Approach to Residual Cardiovascular Risk Management." Frontiers in Cardiovascular Medicine, vol. 7(88); 1-11, 5/13/2020. 10.3389/fcvm.2020.00088. SOURCE Novo Nordisk

South Korea's market leading neurotoxin in aesthetics set to launch in the second half of 2024. NEWPORT BEACH, Calif., March 4, 2024 /PRNewswire/ -- Hugel America, Inc., a division of Hugel Inc., a global leader in the medical aesthetics industry, today announced it received United States (U.S.) Food and Drug Administration (FDA) approval on its neurotoxin, Letybo to treat moderate-to-severe glabellar (frown) lines in adults. In the coming months, Hugel plans to accelerate its transition for approved medical use with the goal of launching to aesthetic clinicians in the back half of 2024. "We are thrilled with the FDA's approval of Letybo. This is a huge achievement for Hugel as we focus on becoming a top aesthetics brand in the U.S.," stated James Hartman, President, Hugel America. "As South Korea's leading neurotoxin brand, our quality facial injectables are trusted by millions and we cannot wait to help even more people achieve their aesthetic aspirations." Joely Kaufman, MD, commented, "The results from the clinical trials for letibotulinumtoxinA demonstrate efficacy, and a convincing safety profile in the treatment of glabellar lines1. These comprehensive outcomes provide me – and will provide my fellow injectors – with a high level of confidence in offering Letybo to patients." FDA approval is supported by positive results from three completed phase III trials that enrolled more than 1,000 subjects in the U.S. and Europe1. This botulinum toxin type A has been the leading neurotoxin brand in South Korea, one of the world's most dynamic aesthetic markets, for seven consecutive years. Hugel has sold over 26 million vials in 50+ different countries including Australia, Canada, and Europe. Letybo is expected to be available throughout the U.S. later this year. Injectors and consumers are encouraged to visit for updates on product availability. IMPORTANT SAFETY INFORMATION for LETYBO®  (letibotulinumtoxinA-wlbg)  Injection LETYBO® may cause serious side effects that can be life threatening. Get medical help right away if you have any of these problems after treatment with LETYBO®:  Problems swallowing, speaking, or breathing, due to weakening of associated muscles can be severe and result in loss of life. You are at the highest risk if these problems are pre-existing before injection. Swallowing problems may last for several months.  Spread of toxin effects. The effect of botulinum toxin may affect areas away from the injection site and cause serious symptoms that include loss of strength and all-over muscle weakness, double vision, blurred vision and drooping eyelids, hoarseness or change or loss of voice, trouble saying words clearly, loss of bladder control, trouble breathing, and trouble swallowing.  Do not receive LETYBO® if you are allergic to any of the ingredients in LETYBO® (see Medication Guide for ingredients); had an allergic reaction to any other botulinum toxin product such as MYOBLOC® (rimabotulinumtoxinB), BOTOX®/BOTOX® COSMETIC (onabotulinumtoxinA), DYSPORT® (abobotulinumtoxinA), XEOMIN® (incobotulinumtoxinA), JEUVEAU® (prabotulinumtoxinA-xvfs), or DAXXIFY® (daxibotulinumtoxinA-lanm); or have a skin infection at the planned injection site; or are a child.  LETYBO® dosing units are not the same as, or comparable to, any other botulinum toxin product. Tell your healthcare provider about all your medical conditions, including side effects from botulinum toxin products, including dry eye; breathing, swallowing, bleeding, or heart problems; plans to have surgery; weakness of forehead muscles, drooping eyelids; have had surgery on your face; are pregnant or breastfeeding or plan to become pregnant or breastfeed. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Especially tell your healthcare provider if you have received any other botulinum toxin product in the last 4 months or any in the past, and exactly which product you received (such as MYOBLOC®, BOTOX®/BOTOX® Cosmetic, DYSPORT®, XEOMIN®, JEUVEAU® or DAXXIFY®). LETYBO® may cause serious side effects, including allergic reactions (such as itching, rash, hives, wheezing, trouble breathing, or dizziness or feeling faint), heart problems (such as irregular heartbeat and heart attack), and eye problems (including dry eye, reduced blinking, and corneal problems). Tell your healthcare provider or get help right away if you experience a serious side effect. No serious side events of distant spread of toxin effect associated with dermatologic use of LETYBO® have been reported in clinical studies at the dose of 20 Units for glabellar lines. The most common side effect of LETYBO® was headache. These are not all the possible side effects of LETYBO®. For more information, see the full Prescribing Information including Boxed Warning, and refer to the Medication Guide or talk with your doctor. To report side effects associated with LETYBO®, please call 1-877-390-2906. You may also report side effects to the FDA at 1-800-FDA-1088 or visit . APPROVED USE LETYBO® is a prescription medicine that is injected into muscles and used in adults to temporarily improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) About Hugel Aesthetics Hugel Aesthetics, headquartered in the US, is a division of Hugel Inc., a global leader in the aesthetics industry. The company has offices in Australia and Canada, with future operations planned for New Zealand. Hugel Aesthetics is dedicated to making aesthetics more attainable for all. For more information, visit: . Contact: Hugel Aesthetics @ [email protected] SOURCE Hugel

TAMPA, Fla., Jan. 27, 2024 /PRNewswire/ -- Thyroid Disease Awareness Month (January) is a pivotal time for raising awareness about the pros and cons of thyroid surgery—one of the most common operations performed in the US. Unfortunately, about 20% of patients having a thyroid operation have something go wrong, resulting in a less than desirable outcome. Continue Reading Thyroid surgery, or thyroidectomy, is typically performed on individuals dealing with thyroid growths, thyroid nodules, thyroid cancers, or overall enlargements of the thyroid gland which are called goiters. Too little thyroid hormone production—called hypothyroidism—is usually not an indication for thyroid surgery. But too much thyroid hormone production (hyperthyroidism) is occasionally treated with thyroid surgery. "Choosing a high-volume thyroid surgeon is pivotal in ensuring successful outcomes and minimizing complications." Post this The relatively high rate of undesirable outcomes stems from the fact that thyroid surgery is highly technical, but many surgeons with little or no specific training are performing this operation. In the US, it is estimated that 80% of thyroid surgery is performed by surgeons who perform less than 10 thyroid operations per year. As predicted, the outcomes for these patients are not as good, with complication rates up to 10 times higher and cure rates for cancer often being up to 25% lower. Thyroid surgery, like most things in life, has better outcomes and higher cure rates when performed by surgeons who do more than 100 of these operations per year. Dr. Gary Clayman, Founder of the Clayman Thyroid Center at the Hospital for Endocrine Surgery in Tampa, Florida emphasizes, "Our mission has always been to provide the highest standard of care for patients. Choosing a very high-volume thyroid surgeon is pivotal in ensuring successful outcomes and minimizing complications, but unfortunately, most people don't do their homework and simply go to the 'local guy' they were referred to. Our thyroid surgeons perform thyroid surgery only—they don't do any other type of surgery." Understanding Thyroid Surgery: Thyroid surgery typically involves removal of half or the entire thyroid gland, depending on the size of the problem and the disease that is being treated. Like all operations, there are potential complications, but these can be decreased to almost zero when the operation is performed by a thyroid surgeon who performs hundreds of thyroid operations per year. With this article for Thyroid Disease Awareness Month, the Clayman Thyroid Center and its world-renowned surgeons hope to educate the public and encourage them to take control of their thyroid health. Dr. Rashmi Roy, widely recognized as the "Goiter Guru" on YouTube, adds, "Informed decisions about who will be your surgeon is the first step toward optimal thyroid health. Education empowers individuals to make choices that positively impact their lives." Common Complications of Thyroid Surgery: Voice Changes: Damage to the vocal cord nerves can lead to hoarseness or changes in voice. The thyroid gland is situated right on top of the recurrent laryngeal nerves and their branches, which control vocal cord movement. Even a slight damage to one of these nerves can cause the patient to lose their voice for months—or even permanently. Dr. Nate Walsh, senior surgeon at the Hospital for Endocrine Surgery, emphasizes, "Inexperienced surgeons have a 10-times higher rate of inadvertently damaging this nerve, leading to temporary or even permanent voice changes, difficulty swallowing, or worst case, difficulty breathing if both nerves are damaged at the same time. That's why it's so important to be mindful in who you are selecting as your surgeon. There can be serious consequences." High-volume surgeons are much more adept at identifying and preserving these very small and delicate nerves to the voice box. The nerves are isolated routinely by high-volume surgeons in every operation whereas low-volume surgeons simply try to avoid this area of the neck which can lead to cancer being left behind. This is a very technical aspect of the operation that is performed with magnification and requires many years of training to become an expert. Dr Clayman adds, "Preservation of vocal cord nerve function is so important that we place an amniotic membrane cover over each nerve during the operation to protect it and help the healing process. It has made a huge difference, to the point that we won't perform thyroid surgery without a biologic covering over the nerve." Bleeding: Excessive bleeding during or after surgery can be a concern, necessitating the expertise to control it. High-volume thyroid surgeons have learned to minimize the risk of bleeding through experience, learning where the potential bleeding points can be hiding. Only by performing a high number of thyroid operations annually (more than 100 per year) can a surgeon gain an in-depth knowledge of the anatomy and the surgery itself along with common and uncommon variations and challenges that may arise with both. This significantly reduces the risk of bleeding during and after a thyroidectomy. Hypoparathyroidism: The four parathyroid glands live on the back side of the thyroid and control the amount of calcium in the bones and blood. The most common complication following thyroid surgery is hypoparathyroidism which occurs when these tiny glands are damaged. As many as 80% of patients undergoing thyroid surgery will experience this problem resulting in low blood calcium problems for weeks or months---or even for their lifetime in 5% of cases. During a thyroidectomy, it is imperative to identify and preserve all the parathyroid glands. Unfortunately, this is difficult to do, with most low-experienced surgeons being unable to find and preserve these tiny glands. Again, multiple medical publications have shown that low-volume surgeons experience this complication as much as ten times more frequently than high-volume thyroid surgeons. Scar Formation: A visible and unsightly scar is often a concern for patients undergoing thyroidectomy. Although the appearance of scars varies from person to person, experienced and skilled thyroid surgeons employ techniques to minimize scarring and promote optimal healing. High-volume thyroid surgeons typically use a plastic surgery type of closure, which helps to ensure a scar that is not visible once completely healed. Dr. Roy has released several YouTube videos about the strategic placement of the incisions and how well the scars heal. The ultimate in scar outcomes is to avoid an incision in the neck altogether. Only a few surgeons offer robotic thyroid surgery, which hides the incisions in the arm pits. The highest volume robotic thyroid surgeon in the US is Dr. Hyunsuk Suh, Medical Director of the Robotic Thyroid Surgery Center at the Hospital for Endocrine Surgery. He performs state-of-the-art robotic thyroid surgery exclusively which leaves behind no neck scar and states: "Robotic thyroid surgery offers the potential for zero scars on their neck, providing patients with both medical and cosmetic benefits." Choosing the Right Thyroid Surgeon: When selecting a thyroid surgeon, do your homework! Dr. Roy created a video to guide you in questions to ask your potential thyroid surgeon. You should also consider: Credentials: Verify specialized training in thyroid surgery. Just being a board- certified general surgeon is not enough. Referrals & Reviews: Seek recommendations from healthcare providers and trusted resources. Check the practice's Google reviews and look up the surgeon on HealthGrades. Seek out testimonials and see what past patients have to say. Experience: Inquire about the surgeon's experience and success rate. Ask how many thyroid operations they perform each year, and ask about their complication rates. If they can't tell you, then you may want to seek another opinion. Communication: Choose a surgeon who promotes open and transparent communication. Hospital Affiliation: Ensure affiliation with a reputable medical center. Conclusion: As we observe Thyroid Disease Awareness Month, it is crucial to prioritize thyroid health and informed decision-making. If you have thyroid cancer, thyroid nodules or another type of thyroid disease, surgery may be necessary – but keep in mind there are steps you can take to minimize the complications, and they begin with choosing an expert thyroid surgeon. About the Clayman Thyroid Center: Founded by one of the nation's best-known thyroid surgeons, the Clayman Thyroid Center is the highest volume thyroid cancer referral center in the United States. The Center boasts the most experienced thyroid surgeons in the US who provide personalized care allowing the greatest opportunity for cancer cure, wellness, and cosmetic, and functional, outcomes via all types of thyroid surgery from minimal incision to scarless thyroid surgery to advanced cancer care. | (813) 940-3130 About the Hospital for Endocrine Surgery The Hospital for Endocrine Surgery is a campus of HCA Florida South Tampa Hospital focused on compassionate patient care and highly specialized treatment of endocrine tumors. We provide a wide array of services necessary for the diagnosis and surgical treatment of tumors of the thyroid, parathyroid, and adrenal glands. Our team includes doctors, surgeons, nurses, and technicians who have dedicated their careers to delivering the highest cure rates using the most advanced techniques available. HCA's Hospital for Endocrine Surgery is the nation's highest-volume hospital for thyroid, parathyroid, and adrenal tumors and cancers. Media Contact: Julie Canan, Director of Marketing 941.468.3002 | [email protected] SOURCE Clayman Thyroid Center